Takeda Pharmaceutical Company Statistics

Total Valuation

Takeda Pharmaceutical Company has a market cap or net worth of JPY 6.51 trillion. The enterprise value is 11.26 trillion.

Market Cap	6.51T
Enterprise Value	11.26T

Important Dates

The next estimated earnings date is Thursday, January 30, 2025.

Earnings Date	Jan 30, 2025
Ex-Dividend Date	Mar 28, 2025

Share Statistics

Takeda Pharmaceutical Company has 1.59 billion shares outstanding. The number of shares has increased by 1.07% in one year.

Current Share Class	n/a
Shares Outstanding	1.59B
Shares Change (YoY)	+1.07%
Shares Change (QoQ)	+1.29%
Owned by Insiders (%)	0.06%
Owned by Institutions (%)	45.08%
Float	1.57B

Valuation Ratios

The trailing PE ratio is 22.55 and the forward PE ratio is 37.86. Takeda Pharmaceutical Company's PEG ratio is 4.03.

PE Ratio	22.55
Forward PE	37.86
PS Ratio	1.42
PB Ratio	0.94
P/TBV Ratio	n/a
P/FCF Ratio	9.60
P/OCF Ratio	n/a
PEG Ratio	4.03

Financial Ratio History

Enterprise Valuation

The stock's EV/EBITDA ratio is 8.14, with an EV/FCF ratio of 16.61.

EV / Earnings	38.82
EV / Sales	2.48
EV / EBITDA	8.14
EV / EBIT	17.13
EV / FCF	16.61

Financial Position

The company has a current ratio of 1.28, with a Debt / Equity ratio of 0.81.

Current Ratio	1.28
Quick Ratio	0.66
Debt / Equity	0.81
Debt / EBITDA	4.07
Debt / FCF	8.28
Interest Coverage	5.49

Financial Efficiency

Return on equity (ROE) is 4.15% and return on invested capital (ROIC) is 3.29%.

Return on Equity (ROE)	4.15%
Return on Assets (ROA)	2.77%
Return on Capital (ROIC)	3.29%
Revenue Per Employee	92.25M
Profits Per Employee	5.88M
Employee Count	49,281
Asset Turnover	0.31
Inventory Turnover	1.31

Taxes

Income Tax	n/a
Effective Tax Rate	n/a

Stock Price Statistics

The stock price has increased by +4.05% in the last 52 weeks.

Beta (5Y)	n/a
52-Week Price Change	+4.05%
50-Day Moving Average	4,181.70
200-Day Moving Average	4,200.00
Relative Strength Index (RSI)	43.79
Average Volume (20 Days)	3,438,545

Short Selling Information

Short Interest	n/a
Short Previous Month	n/a
Short % of Shares Out	n/a
Short % of Float	n/a
Short Ratio (days to cover)	n/a

Income Statement

In the last 12 months, Takeda Pharmaceutical Company had revenue of JPY 4.55 trillion and earned 290.00 billion in profits. Earnings per share was 182.01.

Revenue	4.55T
Gross Profit	3.00T
Operating Income	653.63B
Pretax Income	269.71B
Net Income	290.00B
EBITDA	1.33T
EBIT	653.63B
Earnings Per Share (EPS)	182.01

Full Income Statement

Balance Sheet

The company has 859.02 billion in cash and 5.61 trillion in debt, giving a net cash position of -4,750.38 billion or -2,996.74 per share.

Cash & Cash Equivalents	859.02B
Total Debt	5.61T
Net Cash	-4,750.38B
Net Cash Per Share	-2,996.74
Equity (Book Value)	6.92T
Book Value Per Share	4,365.91
Working Capital	666.78B

Full Balance Sheet

Cash Flow

In the last 12 months, operating cash flow was 876.31 billion and capital expenditures -198.53 billion, giving a free cash flow of 677.78 billion.

Operating Cash Flow	876.31B
Capital Expenditures	-198.53B
Free Cash Flow	677.78B
FCF Per Share	427.57

Full Cash Flow Statement

Margins

Gross margin is 65.95%, with operating and profit margins of 14.38% and 6.38%.

Gross Margin	65.95%
Operating Margin	14.38%
Pretax Margin	5.93%
Profit Margin	6.38%
EBITDA Margin	29.22%
EBIT Margin	14.38%
FCF Margin	14.91%

Dividends & Yields

This stock pays an annual dividend of 196.00, which amounts to a dividend yield of 4.77%.

Dividend Per Share	196.00
Dividend Yield	4.77%
Dividend Growth (YoY)	4.35%
Years of Dividend Growth	1
Payout Ratio	101.62%
Buyback Yield	-1.07%
Shareholder Yield	3.70%
Earnings Yield	4.43%
FCF Yield	10.42%

Dividend Details

Stock Splits

This stock does not have any record of stock splits.

Last Split Date	n/a
Split Type	n/a
Split Ratio	n/a

Scores

Takeda Pharmaceutical Company has an Altman Z-Score of 1.17. A Z-score under 3 suggests an increased risk of bankruptcy.

Altman Z-Score	1.17
Piotroski F-Score	n/a